Infectious Diseases

Overview

The groups of this area aim to improve the outcomes of patients with infectious diseases. During 2020, we have developed basic, translational and clinical research in the field of the COVID-19 infection, including the virus characterization, the study of the mechanisms of pathogenesis, the diagnosis, the epidemiology, the prevention of the disease and the therapeutics and management options to improve the outcome of the infected people. Additionally, we have continued working on the development of strategies to diagnose, prevent and solve clinical problems related to other infectious diseases and in the characterization of the mechanisms of pathogenicity and antimicrobial resistance of different infectious disease agents. Likewise, we have advanced in the research in critical care and sepsis as well as in aspects related to children’s infectious diseases and primary immunodeficiencies.

Publications

298

total

1734

impact factor

5.82

average impact factor

Group Leader: Magda Campins Martí

team

group-zoom

zoom

group-download

download

During 2020 the main focus of our team was the control and prevention of the Covid-19 infection, both in our hospital and in our reference area. One of the highlights of this activity was the collaboration between our team and primary care to conduct containment measures to promptly implement effective prevention and control measures in nursing homes.

Another important line of work that took the spotlight during the pandemic was the development of clinical trials in the search for a safe and effective Covid-19 vaccine.

20

total

77

impact factor

3^.85

average impact factor

SELECTED ARTICLES

Borras-Bermejo B, Martínez-Gómez X, San Miguel MG, Esperalba J, Antón A, Martin E, Selvi M, Abadías MJ, Román A, Pumarola T, Campins M, Almirante B.
Asymptomatic SARS-CoV-2 infection in nursing homes, Barcelona, Spain, April 2020.
Emerg Infect Dis. 2020 Jun;26(9).
DOI: 10.3201/eid2609.202603
IF: 6.2
Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, Campins Marti M, Perez R, González Roncero FM, Kumar D, Chiang YJ, Doucette K, Pipeleers L, Agüera Morales ML, Rodriguez-Ferrero ML, Secchi A, McNeil SA, Campora L, Di Paolo E, El Idrissi M, López-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Z-041 Study Group.
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: a Phase III, Randomized Clinical Trial.
Clin Infect Dis. 2020 Jan 2;70(2):181-190.
DOI: 10.1093/cid/ciz177
IF: 8.3
Dos Santos G, Nguyen BY, Damaso S, Godderis L, Martínez-Gómez X, Eckermann T, Loos H, Salamanca de la Cueva I, Shende V, Schmidt AC, Yeakey A.
Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
Drug Saf. 2020 Mar;43(3):265-279.
DOI: 10.1007/s40264-019-00893-4
IF: 3.4
Abu-Raya B, Maertens K, Edwards KM, Omer SB, Englund JA, Flanagan KL, Snape MD, Amirthalingam G, Leuridan E, Damme PV, Papaevangelou V, Launay O, Dagan R, Campins M, Cavaliere AF, Frusca T, Guidi S, O’Ryan M, Heininger U, Tan T, Alsuwaidi AR, Safadi MA, Vilca LM, Wanlapakorn N, Madhi SA, Giles ML, Prymula R, Ladhani S, Martinón-Torres F, Tan L, Michelin L, Scambia G, Principi N, Esposito S.
Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement.
Front Immunol. 2020 Jun 24;11:1282. eCollection 2020.
DOI: 10.3389/fimmu.2020.01282
IF: 5.09
Tintore M, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Río J, Tur C, Comabella M, Nos C, Arévalo MJ, Anglada E, Menendez R, Midaglia L, Galán I, Vidal-Jordana A, Castilló J, Mulero P, Zabalza A, Rodríguez-Acevedo B, Rodriguez M, Espejo C, Sequeira J, Mitjana R, de Barros A, Pareto D, Auger C, Pérez-Hoyos S, Sastre-Garriga J, Rovira A, Montalban X.
The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS.
Mult Scler. 2020 Nov;26(13):1658-1669. Epub 2019 Oct 15.
DOI: 10.1177/1352458519877810
IF: 5.65

View all publications